

CRESANTO GLOBAL LIMITED

(Formerly known as Raymed Labs Limited)

CIN: L22203UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com
Email- raymedlabs@rediffmail.com, Phone no. 7738669898

To,

BSE Limited,

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001.

Scrip code: 531207

Subject: Outcome of Board Meeting

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., 01st August, 2025, has inter alia considered and approved the following matters:

1. The Board has approved the proposal and the draft scheme for Reduction of Share Capital of the Company in accordance with the provisions of Section 66 of the Companies Act, 2013. The reduction shall be effected in such manner as set out in the draft scheme, subject to the approval of the shareholders and by the Hon'ble National Company Law Tribunal (NCLT).
2. Appointment of M/s. Nidhi Bajaj & Associates, Practicing Company Secretary, as the Secretarial Auditor of the Company for the first term of five consecutive years from the FY 2025-26 to the FY 2029-30.

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 are attached as "Annexure-A".

3. Appointment of Ms. Komal Bajaj, as the Internal Auditor of the Company for the financial year 2025-26.

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 are attached as "Annexure-B".

CRESANTO GLOBAL LIMITED

(Formerly known as Raymed Labs Limited)

CIN: L22203UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com
Email- raymedlabs@rediffmail.com, Phone no. 7738669898

4. Material Related Party Transaction(s) under section 188 of the Companies Act, 2013 and Regulation 23 of SEBI (LODR) Regulations, 2015.

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 are attached as "Annexure-C".

5. Report of Board of Directors along with its Annexures for the Financial Year 2024-25;
6. Fixed the date, time and venue for the Annual General Meeting of the Company;
7. Fixed Book Closure date for the purpose of Annual General Meeting of the Company;
8. Notice for calling 33rd Annual General Meeting of the Company.

The meeting commenced at 11:15 a.m. and concluded at 11:50 a.m.

Kindly take the same on record.

For Cresanto Global Limited

(Formerly known as Raymed Labs Limited)

PRASHANT
NATHMAL
BAJAJ

Digitally signed by
PRASHANT
NATHMAL BAJAJ
Date: 2025.08.01
11:56:51 +05'30'

(Prashant Nathmal Bajaj)

Managing Director

DIN: 06634046

Date: 01st August, 2025

Place: Mumbai

CRESANTO GLOBAL LIMITED

(Formerly known as Raymed Labs Limited)

CIN: L22203UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com
Email- raymedlabs@rediffmail.com, Phone no. 7738669898

"Annexure A"

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024

Sr. No.	Particulars	Information
1.	Name of the Secretarial Auditor	M/s. Nidhi Bajaj & Associates
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment
3.	Date of appointment/ cessation and term of appointment	Appointment of M/s. Nidhi Bajaj & Associates, Practising Company Secretaries as the Secretarial Auditor of the Company for FY 2025-26 to FY 30-31
4.	Brief Profile (in case of appointment)	M/s. Nidhi Bajaj & Associates, Practising Company Secretary Firm (Membership No. 28907, COP No. 14596) Mumbai based firm. The founder of the firm Ms. Nidhi Bajaj possesses more than 10 years of experience in Practice and her area of expertise lies in the field of legal and procedural compliances of various Acts applicable to Corporate like Companies Act 2013, SEBI and FEMA.
5.	Disclosure of relationships between Directors (in case of appointment of a Director)	Not Applicable

CRESANTO GLOBAL LIMITED

(Formerly known as Raymed Labs Limited)

CIN: L22203UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com

Email- raymedlabs@rediffmail.com, Phone no. 7738669898

"Annexure B"

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024

Sr. No.	Particulars	Information
1.	Name of the Secretarial Auditor	Ms. Komal Bajaj
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment
3.	Date of appointment/ cessation and term of appointment	Appointment of Ms. Komal Bajaj as the Internal Auditor of the Company for FY 2025-26
4.	Brief Profile (in case of appointment)	Ms. Komal Bajaj is a MBA professional with more than 10 years of experience in marketing and finance, having a strong background in developing marketing campaigns and driving business growth.
5.	Disclosure of relationships between Directors (in case of appointment of a Director)	Not Applicable

CRESANTO GLOBAL LIMITED

(Formerly known as Raymed Labs Limited)

CIN: L22203UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com
Email- raymedlabs@rediffmail.com, Phone no. 7738669898

"Annexure C"

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024

Sr. No	Particulars	Information
1.	Name of the related party	1. Cresanto India Private Limited 2. Tidagela Ventures Private Limited 3. KVK Packaging LLP 4. K8 Products LLP 5. Koriander Consultants LLP
2.	Nature of relationship [including nature of its interest (financial or otherwise)]	The above related party is an enterprise controlled by common Key Management Personnel and hence falls under the related party under Section 2(76) of the Act and Regulation 2(1)(zb) of the SEBI Listing Regulations.
3.	Type of the proposed transaction	The Company proposes to enter into such Transaction(s)/ contract(s)/ Arrangement(s)/ Agreement(s)/ loan transaction(s)/ sale or purchase of goods or material/ availing or rendering of service(s)/ hiring and let on hire the equipment(s)/ to extend or avail the corporate guarantee in lieu of loan taken and such other business transaction(s) as and when required by and inter-se.
4.	Nature, duration/tenure, material terms, monetary value and particulars of contract/ arrangement	Transactions in the normal course of business with terms and conditions that are generally prevalent in the industry segments that the company is operating in. Monetary value of transactions subject to a maximum as below through contracts/arrangements for a period from

CRESANTO GLOBAL LIMITED

(Formerly known as Raymed Labs Limited)

CIN: L22203UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com

Email- raymedlabs@rediffmail.com, Phone no. 7738669898

		Conclusion of the AGM held in the FY 25-26 to till the AGM to be held in the FY 26-27.
5.	Particulars of the proposed transaction	Same as point 3 above.
6.	Tenure of the transaction	Conclusion of the AGM held in the FY 25-26 to till the AGM to be held in the FY 26-27.
7.	Value of the proposed transaction	<ol style="list-style-type: none">1. Cresanto India Private Limited- 20 Crore2. Tidagela Ventures Private Limited- 7.5 Crore3. KVK Packaging LLP- 7.5 Crore4. K8 Products LLP- 20 Crore5. Koriander Consultants LLP- 7.5 Crore

CRESANTO GLOBAL LIMITED

(Formerly known as Raymed Labs Limited)

CIN: L22203UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com

Email- raymedlabs@rediffmail.com, Phone no. 7738669898

To,

BSE Limited,

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001

Scrip code: 531207

Subject: Outcome of Board Meeting

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., 12th August, 2025, has inter alia considered and approved the following matters:

1. Un-Audited Financial Results of the Company for the first quarter ended 30th June, 2025, together with all the Limited Review report for the first quarter ended 30th June, 2025 prepared in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is attached herewith.

The un-audited financial results for the first quarter ended along with Limited Review Report will be made available on the Company's website.

The meeting commenced at 02:00 p.m. and concluded at 04:00 p.m.

Kindly take the same on record.

For Cresanto Global Limited

(Formerly known as Raymed Labs Limited)

PRASHANT NATHMAL
BAJAJ

Digitally signed by
PRASHANT
NATHMAL BAJAJ
Date: 2025.08.12
16:04:48 +05'30'

(Prashant Nathmal Bajaj)

Managing Director

DIN: 06634046

Date: 12th August, 2025

Place: Mumbai

CRESANTO GLOBAL LIMITED (formerly known as Raymed Labs Limited)

STATEMENT OF UNAUDITED PROFIT AND LOSS FOR THE QUARTER ENDED JUNE 30, 2025

(INR in Lakhs)					
Particulars	Note No.	For the qtr ended June 31, 2025	For the qtr ended March 31, 2025	For the qtr ended June 31, 2024	For the Year ended March 31, 2025
I Revenue					
Revenue from Operations	22	-	-	-	-
Other Income	23	-	51.73	-	52.59
Total Income		-	51.73	-	52.59
II Expenses					
Purchases of Stock in Trade		-	-	-	-
Change in Inventories of Finished Goods/Work-in-progress/ Stock in Tr	24	-	-	-	-
Employee Benefits Expenses	25	3.60	21.05	0.90	21.45
Finance Costs	26	0.01	11.49	-	11.49
Depreciation and Amortization Expenses	27	-	0.29	0.18	0.44
Other Expenses	28	5.60	12.04	0.69	37.26
Total Expenses		9.21	44.87	1.77	70.64
III Profit before tax (I- II)		(9.21)	6.86	(1.77)	(18.05)
IV Less: Tax Expense:					
Current Tax		-	-	-	-
MAT Credit Entitlement		-	-	-	-
Deferred Tax		-	-	-	-
Total Tax Expense		-	-	-	-
V Profit for the Year (III-IV)		(9.21)	6.86	(1.77)	(18.05)
VI Other Comprehensive Income					
<u>Items that will not be reclassified to profit or loss</u>					
Re-measurement gains/ (losses) on defined benefit obligations		-	-	-	-
Tax Effect on above		-	-	-	-
Other Comprehensive Income for the year, net of tax		-	-	-	-
VII Total Comprehensive Income for the year (V+VI) (Comprising Profit and Other Comprehensive Income for the year)		(9.21)	6.86	(1.77)	(18.05)
VIII Earnings Per Equity Share (Face Value INR 10 Per Share):					
Basic and Diluted (INR)	29	(0.22)	0.16	(0.04)	(0.42)
Summary of Significant Accounting Policies	2-4				

The notes referred to above are an integral part of the financial statements

For and on behalf of the Board of Directors

PRASHANT  Digitally signed
by PRASHANT
NATHMAL NATHMAL BAJAJ
BAJAJ Date: 2025.08.12
15:55:53 +05'30'

Prashant Nathmal Bajaj
Managing Director & CFO
DIN- 06634046
Place: Mumbai
Dated: 12.08.2025

Limited Review Report on the Unaudited Quarterly and year-to-date Standalone Financial Results of Cresanto Global Limited (Formerly known as Raymed Labs Limited) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Cresanto Global Limited

1. We have reviewed the accompanying statement of unaudited standalone Financial Results of Cresanto Global Limited (Formerly known as Raymed Labs Limited) (“the Company”) for the quarter ended 30th June 2025 (“the statement”). This statement is being submitted to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (Listing Regulations)
2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (‘Ind AS 34’), prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K T P S & Co.
Chartered Accountants
Firm’s Registration No. 134942W



CA Anurag Khandelia
Partner
Mem. No. 172909
UDIN: 25172909BMIGGZ5502

Place: Mumbai
Date: 12/08/2025